NASDAQ:IMNN Imunon Q3 2025 Earnings Report $5.04 +0.25 (+5.10%) Closing price 03:58 PM EasternExtended Trading$5.04 -0.01 (-0.20%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Imunon EPS ResultsActual EPSN/AConsensus EPS -$1.94Beat/MissN/AOne Year Ago EPSN/AImunon Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImunon Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time11:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Imunon Earnings HeadlinesIMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO CongressOctober 14 at 8:20 AM | globenewswire.comImunon’s IL-12 gene therapy changes “cold” tumour microenvironment to “hot”September 24, 2025 | msn.comIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The company delivered record-breaking revenues in 2024 and Q1 2025, including $72.5 million in net revenue for Q1 — a 73% increase over the prior year — and six consecutive quarters of positive adjusted EBITDA. With cash reserves rising to $30.8 million and a growing patent portfolio of 58 issued and 68 pending patents, BSEM is scaling profitably while advancing its proprietary BioREtain® technology, which has shown clinically superior results for chronic, non-healing wounds. National recognition is adding to the momentum, with CEO Jason Matuszewski named EY Entrepreneur of the Year 2025 Florida Award winner, validating the leadership driving this high-growth MedTech powerhouse.October 16 at 2:00 AM | Huge Alerts (Ad)Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancerSeptember 23, 2025 | finance.yahoo.comIMNN: OVATION 2 Translational Data Shows IMNN-001 Alters Tumor Microenvironment…September 23, 2025 | msn.comImunon: OVATION 2 study results reinforce IMNN-001 efficacy benefitsSeptember 22, 2025 | msn.comSee More Imunon Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Imunon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Imunon and other key companies, straight to your email. Email Address About ImunonImunon (NASDAQ:IMNN), a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.View Imunon ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff Concerns Upcoming Earnings American Express (10/17/2025)HDFC Bank (10/17/2025)Truist Financial (10/17/2025)Intuitive Surgical (10/21/2025)Nasdaq (10/21/2025)Netflix (10/21/2025)Texas Instruments (10/21/2025)Citigroup (10/21/2025)Chubb (10/21/2025)Capital One Financial (10/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
